Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Glucocorticoid-induced osteoporosis.

J A Clowes1, N Peel, R Eastell

  • 1University of Sheffield, Division of Clinical Sciences (North), Northern General Hospital, Sheffield, United Kingdom.

Current Opinion in Rheumatology
|September 14, 2001
PubMed
Summary

Glucocorticoids cause devastating bone loss, leading to a high incidence of fractures in patients. Effective treatments for glucocorticoid-induced osteoporosis (GIO) are underutilized, with many clinical questions remaining.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fat, adipokines, bone structure and bone regulatory factors associations in obesity.

European journal of endocrinology·2022
Same author

Utility of PINP to monitor osteoporosis treatment in primary care, the POSE study (PINP and Osteoporosis in Sheffield Evaluation).

Bone·2022
Same author

The clinical utility of TRACP-5b to monitor anti-resorptive treatments of osteoporosis.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2022
Same author

Evaluation of estimated glomerular function (eGFR) versus creatinine clearance (CrCl) to predict acute kidney injury when using zoledronate for the treatment of osteoporosis.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2021
Same author

Correction to: A Multicenter Study to Evaluate Harmonization of Assays for C-Terminal Telopeptides of Type I Collagen (ß-CTX): A Report from the IFCC-IOF Committee for Bone Metabolism (C-BM).

Calcified tissue international·2021
Same author

A Multicenter Study to Evaluate Harmonization of Assays for C-Terminal Telopeptides of Type I Collagen (ß-CTX): A Report from the IFCC-IOF Committee for Bone Metabolism (C-BM).

Calcified tissue international·2021

Area of Science:

  • Endocrinology
  • Bone Metabolism
  • Pharmacology

Background:

  • Glucocorticoids are essential for managing inflammatory conditions but cause significant bone damage.
  • Glucocorticoid-induced osteoporosis (GIO) affects up to 50% of patients within 6 months, increasing fracture risk by 30-400%.
  • GIO incidence is higher in specific populations, such as organ transplant recipients.

Purpose of the Study:

  • To highlight the significant impact of glucocorticoids on bone health.
  • To address the low utilization of bone-protective therapies for GIO.
  • To identify gaps in understanding GIO pathogenesis and clinical management.

Main Methods:

  • Review of existing literature on glucocorticoid-induced osteoporosis.
  • Analysis of clinical management practices and treatment guidelines.
  • Identification of unresolved questions in GIO research.

Main Results:

  • Glucocorticoid use leads to severe osteoporosis and fractures, with high incidence rates.
  • Bone-active drug prescription for GIO prevention/treatment is notably low in the UK.
  • Key clinical management questions persist regarding intervention thresholds and treatment efficacy.

Conclusions:

  • GIO poses a severe risk, necessitating better management strategies.
  • There is a critical need to increase the use of bone-protective medications for GIO.
  • Further research is required to optimize GIO treatment and fracture prevention.

Related Experiment Videos